

## Find A Researcher

[◀ Previous](#) | [New Search](#) | [Return to Search Results](#) | [Next ▶](#)

### Michael Elliott Weinblatt



▶ [View Physician Profile](#)

Senior Physician, Brigham and Women's Hospital  
John R. Riedman Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital  
Department of Medicine  
Rheumatology, Immunology  
75 Francis Street  
Boston, MA 02115

**Keywords (MeSH):**

Immunoglobulin G  
Receptors, Tumor Necrosis Factor  
Antirheumatic Agents  
Arthritis, Rheumatoid  
Methotrexate

**Publications (Pulled from Harvard Catalyst Profiles):**

1. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al. *Ann Rheum Dis.* 2014 Jan 1; 73(1):e5.
2. Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt ME, Solomon DH. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. *Clin Exp Rheumatol.* 2013 Jul-Aug; 31(4 Suppl 78):S28-32.
3. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Ann Rheum Dis.* 2014 Jan 1; 73(1):86-94.
4. Lin C, Karlson EW, Canhao H, Miller TA, Dligach D, Chen PJ, Perez RN, Shen Y, Weinblatt ME, Shadick NA, Plenge RM, Savova GK. Automatic prediction of rheumatoid arthritis disease activity from the electronic medical records. *PLoS One.* 2013; 8(8):e69932.
5. Iannaccone CK, Fossel A, Tsao H, Cui J, Weinblatt M, Shadick N. Factors associated with attrition in a longitudinal rheumatoid arthritis registry. *Arthritis Care Res (Hoboken).* 2013 Jul; 65(7):1183-9.
6. Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC. Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. *J Rheumatol.* 2013 Jun; 40(6):787-97.
7. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, Turner M, Sutton C, Smith DR, Haney DJ, Chernoff D, Hesterberg LK, Carulli JP, Taylor PC, Shadick NA, Weinblatt ME, Curtis JR. Development of a multi-biomarker disease activity test for rheumatoid arthritis. *PLoS One.* 2013; 8(4):e60635.
8. Lillegraven S, Paynter N, Prince FH, Shadick NA, Haavardsholm EA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, Solomon DH. Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2013 Apr; 65(4):526-33.
9. Cui J, Stahl EA, Saevareddottir S, Miceli C, Diego D, Trzaska G, Bai T, Mirkev M, Canhao H, Ikari K, Terao

#### QUICK LINKS

[FIND A RESEARCHER](#)

[FIND A DOCTOR](#)



[EDIT YOUR PROFILE](#)

#### RELATED LINKS

**Department**

[View all Research Faculty in the Department of Medicine](#)

**Division**

[View all Research Faculty: Rheumatology, Immunology](#)

NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM. Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. *PLoS Genet.* 2013 Mar; 9(3):e1003394.

10. Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. *Arthritis Care Res (Hoboken).* 2013 Mar; 65(3):362-71.

11. Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, Magilavy DB. Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. *J Rheumatol.* 2013 Apr; 40(4):369-78.

12. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. *Arthritis Rheum.* 2013 Jan; 65(1):28-38.

13. Desai SP, Lu B, Szent-Gyorgyi LE, Bogdanova AA, Turchin A, Weinblatt M, Coblyn J, Greenberg JO, Kachalia A, Solomon DH. Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial. *Arthritis Rheum.* 2013 Jan; 65(1):39-47.

14. Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. *Trans Am Clin Climatol Assoc.* 2013; 124:16-25.

15. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. *Ann Rheum Dis.* 2013 Sep 1; 72(9):1445-52.

16. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. *Arthritis Care Res (Hoboken).* 2012 Dec; 64(12):1794-803.

17. Dervieux T, Weinblatt ME, Kivitz A, Kremer JM. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. *Ann Rheum Dis.* 2013 Jun; 72(6):908-10.

18. Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need. *Ann Rheum Dis.* 2012 Nov; 71(11):1757-60.

19. Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, van Vollenhoven RF, Wollenhaupt J, Bingham CO, Duncan B, Goel N, Davies OR, Dougados M. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. *Rheumatology (Oxford).* 2012 Dec; 51(12):2204-14.

20. Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. *Ann Rheum Dis.* 2013 Mar; 72(3):381-9.

21. Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, Iannaccone CK, Weinblatt ME, Solomon DH. Sustained rheumatoid arthritis remission is uncommon in clinical practice. *Arthritis Res Ther.* 2012; 14(2):R68.

22. Chang HH, Tai TS, Lu B, Iannaccone C, Cernadas M, Weinblatt M, Shadick N, Miaw SC, Ho IC. PTPN22.6, a dominant negative isoform of PTPN22 and potential biomarker of rheumatoid arthritis. *PLoS One.* 2012; 7(3):e33067.

23. Ercan A, Cui J, Hazen MM, Batliwalla F, Royle L, Rudd PM, Coblyn JS, Shadick N, Weinblatt ME, Gregersen P, Lee DM, Nigrovic PA. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. *Arthritis Res Ther.* 2012; 14(2):R43.

24. Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, Iannaccone CK, Kvien TK, Haavardsholm EA, Weinblatt ME, Solomon DH. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. *Ann Rheum Dis.* 2012 May; 71(5):681-6.

25. Curtis JR, Chen L, Luijckens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. *Arthritis Rheum.* 2011 Aug; 63(8):2203-8.

26. Lee JS, Wang J, Martin M, Germer S, Kenwright A, Benayed R, Spleiss O, Platt A, Pilson R, Hemmings A, Weinblatt ME, Kaplowitz N, Krasnow J. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. *Pharmacogenet Genomics.* 2011 Jul; 21(7):365-74.

27. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME, Solomon DH. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. *Arthritis Res Ther.* 2011; 13(3):R83.

28. Liao KP, Weinblatt ME, Solomon DH. The end of rheumatoid factor as we know it? *Arthritis Rheum.* 2011 May; 63(5):1170-2.

with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. *Arthritis Rheum.* 2011 Apr; 63(4):894-903.

30. Liao KP, Weinblatt ME, Cui J, Iannaccone C, Chibnik LB, Lu B, Coblyn JS, Shadick NA, Solomon DH. Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. *Rheumatology (Oxford)*. 2011 Aug; 50(8):1473-9.
31. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, Solomon DH. Validation of rheumatoid arthritis diagnoses in health care utilization data. *Arthritis Res Ther.* 2011; 13(1):R32.
32. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. *Arthritis Rheum.* 2011 Feb; 63(2):337-45.
33. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. *J Rheumatol.* 2011 May; 38(5):846-54.
34. Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. *J Rheumatol.* 2011 May; 38(5):855-62.
35. van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijckens K, Keystone EC. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. *Arthritis Care Res (Hoboken)*. 2011 Jan; 63(1):128-34.
36. Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner SW. Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. *J Rheumatol.* 2011 Feb; 38(2):242-6.
37. Coury FF, Weinblatt ME. Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis. *Clin Exp Rheumatol.* 2010 Sep-Oct; 28(5 Suppl 61):S9-12.
38. Desai SP, Turchin A, Szent-Gyorgyi LE, Weinblatt M, Coblyn J, Solomon DH, Kachalia A. Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. *Rheumatology (Oxford)*. 2011 Feb; 50(2):366-72.
39. Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2011 Mar; 63(3):373-82.
40. Tan W, Wu H, Zhao J, Derber LA, Lee DM, Shadick NA, Conn DL, Smith EA, Gersuk VH, Nepom GT, Moreland LW, Furst DE, Thompson SD, Jonas BL, Holers VM, Glass DN, Chen PP, Bridges SL, Weinblatt ME, Paulus HE, Tsao BP. A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. *Arthritis Rheum.* 2010 Oct; 62(10):2864-75.
41. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. *N Engl J Med.* 2010 Sep 30; 363(14):1303-12.
42. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. *Rheumatology (Oxford)*. 2011 Jan; 50(1):40-6.
43. Sullivan MB, Iannaccone C, Cui J, Lu B, Batra K, Weinblatt M, Shadick NA. Evaluation of selected rheumatoid arthritis activity scores for office-based assessment. *J Rheumatol.* 2010 Dec; 37(12):2466-8.
44. Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, O'Donnell CI, Derber LA, Weinblatt ME, Shadick NA, Bell DA, Cairns E, Solomon DH, Holers VM, Rudd PM, Lee DM. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. *Arthritis Rheum.* 2010 Aug; 62(8):2239-48.
45. Curtis JR, Jain A, Askling J, Bridges SL, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. *Semin Arthritis Rheum.* 2010 Aug; 40(1):2-14.e1.
46. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, Hughes LB, de Vries N, Raychaudhuri S, Alfredsson L, Askling J, Wedrén S, Ding B, Guiducci C, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Herenius M, Weinblatt ME, Shadick NA, Worthington J, Batliwalla F, Kern M, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Seldin MF, Moreland LW, Behrens TW, Allaart CF, Criswell LA, Huizinga TW, Tak PP, Bridges SL, Toes RE, Barton A, Klareskog L, Gregersen PK, Karlson EW, Plenge RM. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. *Arthritis Rheum.* 2010 Jul; 62(7):1849-61.
47. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A, Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Brouwer E, Burt NP, Catanese JJ, Coblyn J, Coenen MJ, Costenbader KH, Criswell LA, Crusius JB, Cui J, de Bakker PI, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Lee AT, Liu X, Martin P, Morgan AW, Padyukov L, Posthumus MD, Radstake TR, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, van der Schoot CE, van Riel PL, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth BP, Wijmenga C, Karlson EW, Toes RE, de Vries N, Begovich AB, Worthington J, Siminovitch KA, Gregersen PK, Klareskog L, Plenge RM. Genome-

48. Boillard E, Lai Y, Larabee K, Balestrieri B, Ghomaschi F, Fujioka D, Gobezie K, Coblyn JS, Weinblatt ME, Massarotti EM, Thornhill TS, Divangahi M, Remold H, Lambeau G, Gelb MH, Arm JP, Lee DM. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. *EMBO Mol Med.* 2010 May; 2(5):172-87.
49. Boillard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O'Donnell E, Farndale RW, Ware J, Lee DM. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. *Science.* 2010 Jan 29; 327(5965):580-3.
50. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. *Ann Rheum Dis.* 2010 Jan; 69 Suppl 1:i2-29.
51. Desai SP, Gravalles EM, Shadick NA, Glass R, Cui J, Frits M, Chibnik LB, Maher N, Weinblatt ME, Solomon DH. Hand bone mineral density is associated with both total hip and lumbar spine bone mineral density in post-menopausal women with RA. *Rheumatology (Oxford).* 2010 Mar; 49(3):513-9.
52. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, Catanese JJ, Xie G, Stahl EA, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Burt NP, Chang M, Coblyn J, Costenbader KH, Criswell LA, Crusius JB, Cui J, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Kurzeeman FA, Lee AT, Liu X, Li Y, Martin P, Morgan AW, Padyukov L, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth P, Alshuler D, Karlson EW, Toes RE, de Vries N, Begovich AB, Siminovitch KA, Worthington J, Klareskog L, Gregersen PK, Daly MJ, Plenge RM. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. *Nat Genet.* 2009 Dec; 41(12):1313-8.
53. Zella GC, Weinblatt ME, Winter HS. Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease. *J Pediatr Gastroenterol Nutr.* 2009 Sep; 49(3):355-8.
54. Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, Mesquita SM, Ergul E, Conta JH, Korn JM, McCarroll SA, Gorham JM, Gabriel S, Alshuler DM, Quintanilla-Dieck Mde L, Artunduaga MA, Eavey RD, Plenge RM, Shadick NA, Weinblatt ME, De Jager PL, Hafler DA, Breitbart RE, Seidman JG, Seidman CE. De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. *Nat Genet.* 2009 Aug; 41(8):931-5.
55. Stoll ML, Solomon DH, Batra KL, Simard JF, Karlson EW, Dellaripa PF, Weinblatt ME, Glass R, Shadick NA. TNFalpha inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma. *J Clin Rheumatol.* 2009 Jun; 15(4):198-200.
56. Solomon DH, Finkelstein JS, Shadick N, LeBoff MS, Winalski CS, Stedman M, Glass R, Brookhart MA, Weinblatt ME, Gravalles EM. The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. *Arthritis Rheum.* 2009 Jun; 60(6):1624-31.
57. Weinblatt ME, Abbott GF, Koreishi AF. Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung. *N Engl J Med.* 2009 Apr 23; 360(17):1770-9.
58. Cui J, Taylor KE, Destefano AL, Criswell LA, Izmailova ES, Parker A, Roubenoff R, Plenge RM, Weinblatt ME, Shadick NA, Karlson EW. Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. *Mol Med.* 2009 May-Jun; 15(5-6):136-43.
59. Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. *J Rheumatol.* 2009 Mar; 36(3):546-51.
60. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. *Rheumatology (Oxford).* 2009 Jun; 48(6):613-7.
61. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Ann Rheum Dis.* 2008 Dec; 67 Suppl 3:iii2-25.
62. Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? *Ann Rheum Dis.* 2008 Nov; 67(11):1497-8.
63. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. *Arthritis Rheum.* 2008 Nov; 58(11):3309-18.
64. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Arthritis Rheum.* 2008 Oct 15; 59(10):1371-7.
65. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M,



**65. Weinblatt ME, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH. Therapeutic drug monitoring: early, low-dose biologics recommendations. Am Rheum Dis. 2008 Oct; 67(10):1360-4.**

**66. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, Gianniny L, Korman BD, Padyukov L, Kurreeman FA, Chang M, Catanese JJ, Ding B, Wong S, van der Helm-van Mil AH, Neale BM, Coblyn J, Cui J, Tak PP, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Criswell LA, Amos CI, Seldin MF, Kastner DL, Ardlie KG, Alfredsson L, Costenbader KH, Altshuler D, Huizinga TW, Shadick NA, Weinblatt ME, de Vries N, Worthington J, Seielstad M, Toes RE, Karlson EW, Begovich AB, Klareskog L, Gregersen PK, Daly MJ, Plenge RM. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet. 2008 Oct; 40(10):1216-23.**

**67. Weinblatt ME. Questions and answers in 2008 about biologics in rheumatoid arthritis. J Rheumatol. 2008 Sep; 35(9):1878-81.**

**68. Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, Avorn J, Solomon DH. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008; 10(4):R95.**

**69. Lutt JR, Pisculli ML, Weinblatt ME, Deodhar A, Winthrop KL. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol. 2008 Aug; 35(8):1683-5.**

**70. Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2008 Sep; 35(9):1737-44.**

**71. Johnsen AK, Plenge RM, Butty V, Campbell C, Dieguez-Gonzalez R, Gomez-Reino JJ, Shadick N, Weinblatt M, Gonzalez A, Gregersen PK, Benoist C, Mathis D. A broad analysis of IL1 polymorphism and rheumatoid arthritis. Arthritis Rheum. 2008 Jul; 58(7):1947-57.**

**72. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008 Jul; 58(7):1921-30.**

**73. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008 Aug; 156(2):336-41.**

**74. Todd DJ, Weinblatt ME. Oral versus parenteral administration of methotrexate for the treatment of active RA. Nat Clin Pract Rheumatol. 2008 Jul; 4(7):342-3.**

**75. Roubenoff R, Beckman E, Weinblatt M, Shadick N, Gregersen PK. Biological significance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis. Ann Intern Med. 2008 Mar 4; 148(5):403; author reply 403-4.**

**76. Furst DE, Halbert RJ, Bingham CO, Fukudome S, Anderson L, Bonafede P, Bray V, Cohen SB, Sherrer YR, St Clair EW, Tesser JR, Weinblatt M, Dubois RW. Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. Rheumatology (Oxford). 2008 Feb; 47(2):194-9.**

**77. Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, Kim YG, Henry GW, Shadick NA, Weinblatt ME, Lee DM, Rudd PM, Dwek RA. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem. 2008 May 1; 376(1):1-12.**

**78. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice M, Parkin M, Barry R, Winslow W, Healy C, Graham RR, Neale BM, Izmailova E, Roubenoff R, Parker AN, Glass R, Karlson EW, Maher N, Hafler DA, Lee DM, Seldin MF, Remmers EF, Lee AT, Padyukov L, Alfredsson L, Coblyn J, Weinblatt ME, Gabriel SB, Purcell S, Klareskog L, Gregersen PK, Shadick NA, Daly MJ, Altshuler D. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 2007 Dec; 39(12):1477-82.**

**79. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007 Nov; 66 Suppl 3:iii2-22.**

**80. Bijlsma JW, Weinblatt ME. Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis. 2007 Nov; 66(11):1409-10.**

**81. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007 Aug 15; 57(6):928-34.**

**82. Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME. Peripheral blood expression of nuclear factor-kappaB-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep; 34(9):1817-22.**

**83. Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis. 2008 Mar; 67(3):358-63.**

**84. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.**

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.